

Instance: composition-en-805dc9ddc6fcbad674af5feb9b21aed5
InstanceOf: CompositionUvEpi
Title: "Composition for maviret Package Leaflet"
Description:  "Composition for maviret Package Leaflet"
Usage: #example

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mock)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - maviret"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #en
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What is in this leaflet</p>
<ol>
<li>What Maviret is and what it is used for</li>
<li>What you need to know before you take Maviret</li>
<li>How to take Maviret</li>
<li>Possible side effects</li>
<li>How to store Maviret</li>
<li>Contents of the pack and other information</li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What maviret is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What maviret is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Maviret is an antiviral medicine used to treat adults and children 3 years and older with long-term
( chronic ) hepatitis C. This is an infectious disease that affects the liver, caused by the hepatitis C 
virus. Maviret contains the active substances glecaprevir and pibrentasvir.
Maviret works by stopping the hepatitis C virus from multiplying and infecting new cells. This allows
the infection to be eliminated from the body.</p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take maviret"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take maviret"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Do not take Maviret if:</p>
<p>you are allergic to glecaprevir, pibrentasvir or any of the other ingredients of this medicine 
(listed in section 6).</p>
<p>you have severe liver problems other than from hepatitis C.</p>
<p>you are taking the following medicines:</p>
<p>atazanavir (for HIV infection)</p>
<p>atorvastatin or simvastatin (to lower blood cholesterol)</p>
<p>carbamazepine, phenobarbital, phenytoin, primidone (normally used for epilepsy)</p>
<p>dabigatran etexilate (to prevent blood clots)</p>
<p>ethinyl oestradiol-containing medicines (such as contraception medicines, including 
vaginal rings, transdermal patches, and tablets)</p>
<p>rifampicin (for infections)</p>
<p>St. John s wort (Hypericum perforatum) (herbal remedy used for mild depression).
Do not take Maviret if any of the above apply to you. If you are not sure, talk to your doctor or 
pharmacist before taking Maviret.
Warnings and precautions
Talk to your doctor if you have the following because your doctor may want to check you more 
closely:</p>
<p>liver problems other than hepatitis C</p>
<p>current or previous infection with the hepatitis B virus</p>
<p>diabetes. You may need closer monitoring of your blood glucose levels and/or adjustment of 
your diabetes treatment after starting Maviret. Some diabetic patients have experienced low 
sugar levels in the blood (hypoglycaemia) after starting treatment with medicines like Maviret.
Blood tests 
Your doctor will test your blood before, during and after your treatment with Maviret. This is so that
your doctor can decide if:</p>
<p>you should take Maviret and for how long</p>
<p>your treatment has worked and you are free of the hepatitis C virus.
Children
Do not give this medicine to children under 3 years of age or weighing less than 12 kg. The use of 
Maviret in children under 3 years of age or weighing less than 12 kg has not yet been studied.
Other medicines and Maviret
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other 
medicines.
Tell your doctor or pharmacist before taking Maviret, if you are taking any of the medicines in the 
table below. The doctor may need to change your dose of these medicines.
Medicines you must tell your doctor about before taking Maviret
Medicine
Purpose of the medicine
ciclosporin, tacrolimus
to suppress the immune system
darunavir, efavirenz, lopinavir, ritonavir
for HIV infection 
digoxin
for heart problems
fluvastatin, lovastatin, pitavastatin, pravastatin, 
rosuvastatin 
to lower blood cholesterol
warfarin and other similar medicines<em> to prevent blood clots
</em>Your doctor may need to increase the frequency of your blood tests to check how well your blood 
can clot.
If any of the above apply to you (or you are not sure), talk to your doctor or pharmacist before taking 
Maviret.
Pregnancy and contraception
The effects of Maviret during pregnancy are not known. If you are pregnant, think you may be 
pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine, as the 
use of Maviret in pregnancy is not recommended. Contraceptive medicines that contain 
ethinylestradiol must not be used in combination with Maviret.
Breast-feeding
Talk to your doctor before taking Maviret if you are breast-feeding. It is not known whether the two 
medicines in Maviret pass into breast milk.
Driving and using machines
Maviret should not affect your ability to drive or use any tools or machines.
Maviret contains lactose
If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor 
before taking this medicine.
Maviret contains sodium
This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially 
 sodium-free .</p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take maviret"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take maviret"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor 
or pharmacist if you are not sure. Your doctor will tell you how long you need to take Maviret for.
Maviret tablets are intended for adults, children 12 years and older, or children weighing 45 kg or 
more. Maviret coated granules are intended for children aged 3 years to less than 12 years and
weighing 12 kg to less than 45 kg.
How much to take
The recommended dose for adults, children aged 12 years and older, or children weighing at least 
45 kg is three tablets of Maviret 100 mg/40 mg taken together, once a day.
Three tablets in one blister is the daily dose.
How to take</p>
<p>Take the tablets with food.</p>
<p>Swallow the tablets whole.</p>
<p>Do not chew, crush or break the tablets as it may affect the amount of Maviret in your blood.
If you are sick (vomit) after taking Maviret it may affect the amount of Maviret in your blood. This
may make Maviret work less well.</p>
<p>If you vomit less than 3 hours after taking Maviret, take another dose.</p>
<p>If you vomit more than 3 hours after taking Maviret, you do not need to take
another dose until your next scheduled dose.
If you take more Maviret than you should
If you accidentally take more than the recommended dose, contact your doctor or go to the nearest 
hospital straight away. Take the medicine pack with you so that you can show the doctor what you 
have taken.
If you forget to take Maviret
It is important not to miss a dose of this medicine.
If you do miss a dose, work out how long it is since you should have last taken Maviret:</p>
<p>If you notice within 18 hours of the time you usually take Maviret, take the dose as soon as 
possible. Then take the next dose at your usual time.</p>
<p>If you notice 18 hours or more after the time you usually take Maviret, wait and take the next 
dose at your usual time. Do not take a double dose to make up for a forgotten tablet.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.
Tell your doctor or pharmacist if you notice any of the following side effects:
Very common: may affect more than 1 in 10 people</p>
<p>feeling very tired (fatigue)</p>
<p>headache
Common: may affect up to 1 in 10 people</p>
<p>feeling sick (nausea)</p>
<p>diarrhoea</p>
<p>feeling weak or lack of energy (asthenia)</p>
<p>increase in a laboratory test of liver function (bilirubin)
Uncommon: may affect up to 1 in 100 people </p>
<p>swelling of the face, lips, tongue, throat, abdomen, arms or legs
Not known: cannot be estimated from the available data</p>
<p>itching
Reporting of side effects
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects 
not listed in this leaflet. You can also report side effects directly via the national reporting system 
listed in Appendix V. By reporting side effects you can help provide more information on the safety of 
this medicine.</p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store maviret"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store maviret"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton and blister after EXP. The 
expiry date refers to the last day of that month.
This medicine does not require any special storage conditions.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to 
throw away medicines you no longer use. These measures will help protect the environment.</p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What Maviret contains </p>
<p>The active substances are glecaprevir and pibrentasvir. Each tablet contains 100 mg of 
glecaprevir and 40 mg of pibrentasvir.</p>
<p>The other ingredients are:</p>
<p>Tablet core: copovidone (Type K 28), vitamin E polyethylene glycol succinate, silica, 
anhydrous colloidal, propylene glycol monocaprylate (type II), croscarmellose sodium, 
sodium stearyl fumarate.</p>
<p>Tablet film-coating: hypromellose (E464), lactose monohydrate, titanium dioxide, macrogol 
3350, iron oxide red (E172).
Maviret contains lactose and sodium. See section 2. What Maviret looks like and contents of the pack
Maviret tablets are pink, oblong, curved on both sides (biconvex), film-coated tablets (tablets) with 
dimensions of 18.8 mm x 10.0 mm and debossed on one side with  NXT .
Maviret tablets are packed into foil blisters, each containing 3 tablets. Maviret is available in a pack of 
84 tablets as 4 cartons, each containing 21 film-coated tablets.
Marketing Authorisation Holder
AbbVie Deutschland GmbH &amp; Co. KG
Knollstrasse
67061 Ludwigshafen
Germany
Manufacturer
AbbVie Deutschland GmbH &amp; Co. KG
Knollstrasse
67061 Ludwigshafen
Germany
or
AbbVie Logistics B.V
Zuiderzeelaan 8017 JV Zwolle
Netherlands
For any information about this medicine, please contact the local representative of the Marketing 
Authorisation Holder:
Belgi /Belgique/Belgien
AbbVie SA
T l/Tel: +32 10  477Lietuva
AbbVie UAB 
Tel: +370 5 205 3 </p>
<p>.: +359 2 90 30 Luxembourg/Luxemburg
AbbVie SA
Belgique/Belgien
T l/Tel: +32 10 477 esk  republika
AbbVie s.r.o. 
Tel: +420 233 098 Magyarorsz g
AbbVie Kft.
Tel.: +36 1 455 8Danmark
AbbVie A/S
Tlf: +45 72 30-20-Malta
V.J.Salomone Pharma Limited 
Tel: +356 22983Deutschland
AbbVie Deutschland GmbH &amp; Co. KG
Tel: 00800 222843 33 (geb hrenfrei)
Tel: +49 (0) 611 / 1720-0
Nederland
AbbVie B.V.
Tel: +31 (0)88 322 2Eesti
AbbVie O 
Tel: +372 623 1Norge
AbbVie AS
Tlf: +47 67 81 80<br />
AbbVie    . .
 : +30 214 4165  sterreich
AbbVie GmbH 
Tel: +43 1 20589-0
Espa a
AbbVie Spain, S.L.U. 
Tel: +34 91 384 09 Polska
AbbVie Sp. z o.o.
Tel.: +48 22 372 78 France
AbbVie
T l: +33 (0)1 45 60 13 Portugal
AbbVie, Lda. 
Tel: +351 (0)21 1908Hrvatska 
AbbVie d.o.o.
Tel: +385 (0)1 5625 Rom nia
AbbVie S.R.L.
Tel: +40 21 529 30 Ireland
AbbVie Limited 
Tel: +353 (0)1 4287Slovenija
AbbVie Biofarmacevtska dru ba d.o.o.
Tel: +386 (1)32 08  sland
Vistor hf.
S mi: +354 535 7Slovensk  republika
AbbVie s.r.o.
Tel: +421 2 5050 0Italia
AbbVie S.r.l. 
Tel: +39 06 928Suomi/Finland
AbbVie Oy 
Puh/Tel: +358 (0)10 2411<br />
Lifepharma (Z.A.M.) Ltd
 : +357 22 34 74 Sverige
AbbVie AB
Tel: +46 (0)8 684 44 Latvija
AbbVie SIA 
Tel: +371 67605United Kingdom (Northern Ireland)
AbbVie Deutschland GmbH &amp; Co. KG
Tel: +44 (0)1628 561This leaflet was last revised in
Other sources of information
Detailed information on this medicine is available on the European Medicines Agency web site: </p>         </div>"""      

